The Zhitong Finance App learned that Morgan Stanley released a research report stating that it maintains Hengrui Pharmaceutical's (01276) target price of HK$82 and an “increase in weight” rating. The bank said that the weekly oral administration field is still very early, and the number of global competitors is limited. The $300 million down payment is “quite impressive” for an asset that is still in the IND/Phase 1 phase. The deal once again shows that global pharmaceutical companies still attach great importance to the obesity market; Hengrui GLP-1 platform is globally competitive.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.